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Background: Antibiotic resistance, either intrinsic or 
acquired, is a major obstacle for treating bacterial infec-
tions. Aim: Our objective was to compare the country-
specific species distribution of the four Gram-negative 
species  Escherichia coli,  Klebsiella pneumoniae, 
Pseudomonas aeruginosa  and  Acinetobacter  species 
and the proportions of selected acquired resistance 
traits within these species. Method: We used data 
reported for 2016 to the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) by 
30 countries in the European Union and European 
Economic Area. Results: The country-specific spe-
cies distribution varied considerably. While  E. 
coli accounted for 31.9% to 81.0% (median: 69.0%) of all 
reported isolates, the two most common intrinsically 
resistant species P. aeruginosa and Acinetobacterspp. 
combined (PSEACI) accounted for 5.5% to 39.2% of 
isolates (median: 10.1%). Similarly, large national dif-
ferences were noted for the percentages of acquired 
non-susceptibility to third-generation cephalospor-
ins, carbapenems and fluoroquinolones. There was a 
strong positive rank correlation between the country-
specific percentages of PSEACI and the percentages of 
non-susceptibility to the above antibiotics in all four 
species (rho > 0.75 for 10 of the 11 pairs of variables 
tested). Conclusion: Countries with the highest propor-
tion of P. aeruginosa and Acinetobacter spp. were also 
those where the rates of acquired non-susceptibility in 
all four studied species were highest. The differences 
are probably related to national differences in antibi-
otic consumption and infection prevention and control 
routines.
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Introduction
Bloodstream infections constitute a major dis-
ease burden in Europe. Gram-negative bac-
teria such as  Escherichia coli,  Klebsiella 
pneumoniae,  Pseudomonas aerugi-
nosa and Acinetobacter  species are the most common 
organisms involved in these infections. Data from 
the European Antimicrobial Resistance Surveillance 
Network (EARS-Net) show that the proportional 
contribution of each bacterial species to the total 
number of blood isolates varies considerably between 
countries [1]. In particular  Acinetobacter  spp. and  P. 
aeruginosa  seem to be proportionally far more 
commonly isolated in some European countries than in 
others. Several studies have previously made the same 
observation [2-4].
Antibiotic resistance is a major obstacle for treat-
ing these serious infections. Resistance can be both 
intrinsic, i.e. due to a species’ innate ability to resist 
a particular antibiotic because of structural or func-
tional characteristics, or acquired though a range of 
resistance mechanisms emerging either by mutation or 
acquisition of novel genes.
Among Gram-negative bacteria, intrinsic resistance 
varies markedly between species. For example, even 
wild-type isolates of  K. pneumoniae  are intrinsically 
resistant to penicillins whereas wild-type isolates of E. 
coli are susceptible to the same antibiotics. More impor-
tantly, every wild-type isolate of  Acinetobacter  spp. 
and P. aeruginosa is intrinsically resistant to numerous 
groups of antibiotics (e.g. aminopenicillin-β-lactamase 
inhibitor combinations, first- and second-generation 
cephalosporins, cefotaxime/ceftriaxone, ertapenem, 
trimethoprim, tetracyclines and older quinolones) 
[5], immediately excluding these as possible treat-
ment alternatives. Acquisition of additional resistance 
traits can further reduce available treatment options, 
jeopardise the use of major remaining groups of anti-
biotics including β-lactams, fluoroquinolones and ami-
noglycosides. Bacteria can acquire multiple resistance 
mechanisms, leading to multidrug-resistant (MDR), 
extensively drug-resistant (XDR) or even pandrug-
resistant (PDR) isolates [6]. Thus the overall pattern 
of resistance as presented in the laboratory reports 
reflects the intrinsic resistance characteristics of the 
species combined with any additional resistance trait 
acquired by the isolate.
Similar to the differences in the distribution of Gram-
negative species between European countries, EARS-Net 
has also documented large differences in the percent-
age of acquired antibiotic resistance [1,2]. However, 
there is no study addressing the possible link between 
the ranking of the various species of Gram-negative 
bacteria and the percentage of acquired resistances 
in these species. As an example, most publications on 
resistance in P. aeruginosa and Acinetobacter spp. only 
focus on acquired resistance mechanisms or on clonal 
expansion of resistant epidemic clones, and a few 
others describe the intrinsic resistance characteristics 
of these species [7-10]. Correlation between intrin-
sic and acquired resistance is mentioned only from 
a mechanistic perspective, such as the link between 
inducible and de-repressed production of chromo-
somal AmpC β-lactamase [8], but not from a statistical 
or epidemiological point of view.
The objective of the present study was to assess the 
association between the proportion of the two most 
common intrinsically resistant species (P. aerugi-
nosa  and  Acinetobacter  spp.) among the four major 
Gram-negative species (E. coli, K. pneumoniae, P. aer-
uginosa and Acinetobacter spp.) and the percentage of 
selective acquired resistance traits in these species. 
As the data source, we used data reported to EARS-Net 
for countries in the European Union (EU) and European 
Economic Area (EEA) in the year 2016.
Methods
Data source and inclusion criteria
EARS-Net is a surveillance network which collects 
and analyses data from routine antibiotic susceptibil-
ity testing (AST) of bacterial pathogens from all 28 EU 
countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, 
the Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, the Netherlands, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden and the United Kingdom) and two EEA coun-
tries (Iceland and Norway). The network is coordinated 
by the European Centre for Disease Prevention and 
Control (ECDC). Only AST results for selected impor-
tant antibiotics active against invasive bacterial infec-
tions are included in EARS-Net. The AST results are 
ascertained according to agreed protocols [1] and the 
general quality and comparability of the data are eval-
uated through an annual external quality assessment 
exercise distributed to the participating laboratories.
Data on  E. coli,  K. pneumoniae,  P. aeruginosa, 
and  Acinetobacter  spp. isolates reported to EARS-Net 
for the year 2016 were extracted from The European 
Surveillance System (TESSy) database at ECDC. Data 
included isolates from blood and cerebrospinal fluid, 
both considered as markers of bloodstream infections. 
Data were de-duplicated to only include the first iso-
late per species, patient and year. For this study, only 
data from laboratories reporting observations for at 
least three of the four above-mentioned species were 
included. The study was limited to only include antibi-
otics commonly used for first-line treatment of bacte-
remia caused by Gram-negative species and routinely 
included in susceptibility testing in most local clinical 
laboratories in Europe. The AST information for the fol-
lowing antibiotic–species combinations were included 
in the study dataset: third-generation cephalosporins 
(ceftriaxone, ceftazidime or cefotaxime for E. coli, and K. 
pneumoniae; ceftazidime for P. aeruginosa), carbapen-
ems (meropenem or imipenem, for all four species) and 
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fluoroquinolones (ciprofloxacin, levofloxacin or oflox-
acin for  E. coli  and  K. pneumoniae; ciprofloxacin or 
levofloxacin for  P. aeruginosa  and  Acinetobacter  spp.) 
Isolates were considered as non-susceptible when 
reported as either intermediately susceptible (I) or 
resistant (R).
Of the 829 laboratories that reported data on any of 
the targeted species to EARS-Net for the year 2016 
(total: 176,082 isolates), 749 fulfilled the inclusion cri-
terion (total: 173,540 isolates) and were included in the 
final analysis.
Statistical analysis
The percentages of  E. coli,  K. pneumoniae,  P. aerugi-
nosa, and Acinetobacter spp. isolates among the total of 
isolates included in the study, as well as the sum of the 
percentages of  P. aeruginosa  and  Acinetobacter  spp. 
(PSEACI) were calculated for each country. Rank com-
parison of the percentages of acquired non-suscepti-
bility in each of the four Gram-negative species with 
the percentage of PSEACI was performed using the 
Spearman’s rank correlation coefficient to assess the 
monotonic relationships and limit impact of outliers.
Table 1
Number of reported isolates (n = 176,082) and included isolates (n = 173,540) of the four targeted species, and percentage of 
total per country and species, EU/EEA, 2016
Country
Isolates 
reported to 
EARS-Net
Isolates 
included in 
this studya
Escherichia coli Klebsiella pneumoniae
Pseudomonas 
aeruginosa Acinetobacterspecies
N n n % n % n % n %
Austria 7,310 7,300 5,276 72.3 1,247 17.1 696 9.5 81 1.1
Belgium 4,970 4,610 3,538 76.7 669 14.5 334 7.2 69 1.5
Bulgaria 564 479 190 39.7 146 30.5 56 11.7 87 18.2
Croatia 1,810 1,771 1,020 57.6 312 17.6 259 14.6 180 10.2
Cyprus 317 317 149 47.0 75 23.7 64 20.2 29 9.1
Czech Republic 4,982 4,818 3,026 62.8 1,304 27.1 431 8.9 57 1.2
Denmark 6,535 6,535 4,847 74.2 1,156 17.7 460 7.0 72 1.1
Estonia 949 905 667 73.7 174 19.2 56 6.2 8 0.9
Finland 5,983 5,983 4,833 80.8 770 12.9 352 5.9 28 0.5
France 16,387 16,387 11,337 69.2 2,608 15.9 1,988 12.1 454 2.8
Germany 20,359 20,186 15,619 77.4 2,809 13.9 1,320 6.5 438 2.2
Greece 4,097 4,095 1,305 31.9 1,183 28.9 704 17.2 903 22.1
Hungary 3,859 3,840 1,990 51.8 720 18.8 731 19.0 399 10.4
Iceland 237 237 192 81.0 25 10.5 17 7.2 3 1.3
Ireland 3,755 3,597 2,855 79.4 439 12.2 240 6.7 63 1.8
Italy 10,339 9,703 5617 57.9 2,191 22.6 1,207 12.4 688 7.1
Latvia 446 393 218 55.5 85 21.6 16 4.1 74 18.8
Lithuania 1,284 1,265 783 61.9 321 25.4 74 5.8 87 6.9
Luxembourg 545 545 419 76.9 78 14.3 40 7.3 8 1.5
Malta 477 477 328 68.8 102 21.4 40 8.4 7 1.5
Netherlands 8,184 7,841 6,123 78.1 1,067 13.6 543 6.9 108 1.4
Norway 4,689 4,689 3,618 77.2 811 17.3 227 4.8 33 0.7
Poland 4,674 4,557 2,641 58.0 1,128 24.8 403 8.8 385 8.4
Portugal 9,575 9,513 5,740 60.3 2,338 24.6 1,229 12.9 206 2.2
Romania 1,017 956 403 42.2 328 34.3 82 8.6 143 15.0
Slovakia 1,601 1,570 807 51.4 458 29.2 191 12.2 114 7.3
Slovenia 1,890 1,890 1,420 75.1 267 14.1 143 7.6 60 3.2
Spain 9,429 9,389 6,761 72.0 1,679 17.9 843 9.0 106 1.1
Sweden 9,066 8,975 6,921 77.1 1,495 16.7 473 5.3 86 1.0
United Kingdom 30,752 30,717 23,685 77.1 4,232 13.8 2,186 7.1 614 2.0
Total 176,082 173,540 122,328 70.5 30,217 17.4 15,405 8.9 5,590 3.2
EARS-Net: European Antimicrobial Resistance Surveillance Network; EU/EEA: European Union and European Economic Area.
a Limited to laboratories reporting observations for at least three of the four species E. coli, K. pneumoniae, P. aeruginosa and 
Acinetobacter spp.
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All statistical analyses were performed using Stata 
Statistical Software Release 14 (StataCorp, College 
Station, United States).
Ethical statement
Antimicrobial resistance is listed as a special health 
issue in the EU case definitions for which ECDC rou-
tinely collects, analyses and disseminates surveillance 
data as stated by the Article 3 of its founding regula-
tion. TESSy data are pseudonymised and processed for 
public interest in the area of public health. Approval 
of the study by an ethics committee was therefore not 
necessary.
Results
Distribution of the species
Overall,  E. coli  was the most commonly reported 
species (70.5%), followed by K. pneumoniae (17.4%), P. 
aeruginosa(8.9%) and  Acinetobacter  spp. (3.2%) 
Table 2
Percentage of non-susceptible isolates (I or R) per country, antibiotic group and species, EU/EEA, 2016 (n = 173,540)
Country
Escherichia coli Klebsiella pneumoniae
Pseudomonas 
aeruginosa Acinetobacterspecies
Composite  
 
% IR to 
broad-
spectrum 
β-lactamsa
Composite  
 
% IR to FQb
% IR to  
 
3GC
% IR 
to  
 
car
% IR 
to  
 
FQ
% IR 
to  
 
3GC
% IR 
to  
 
car
% IR 
to  
 
FQ
% IR 
to  
 
3GC
% IR 
to  
 
car
% IR 
to  
 
FQ
% IR to  
 
car
% IR to  
 
FQ
Austria 10.4 <0.1 20.5 10.6 0.9 11.8 11.6 17.0 9.1 13.6 16.0 11.1 17.9
Belgium 11.1 0.1 25.4 23.5 3.0 27.1 8.3 12.6 17.1 1.5 11.8 12.9 24.8
Bulgaria 41.0 1.1 43.3 75.9 6.9 64.8 38.9 33.9 35.7 77.0 64.4 57.4 52.8
Croatia 15.6 0.0 29.4 50.0 1.9 46.3 20.5 47.9 39.9 95.0 94.8 34.4 40.4
Cyprus 30.2 0.7 47.0 32.0 12.0 37.3 10.9 26.6 21.9 71.4 71.4 33.5 41.8
Czech Republic 16.2 0.1 31.6 52.7 0.4 50.7 18.6 20.5 33.0 7.0 17.5 26.4 36.7
Denmark 8.1 0.0 13.8 9.9 0.4 8.3 4.5 4.6 5.0 0.0 2.8 8.1 12.1
Estonia 10.5 0.0 14.9 34.5 0.6 35.6 17.6 22.2 5.4 37.5 40.0 16.1 18.5
Finland 7.6 <0.1 12.3 5.3 0.3 4.9 5.4 10.8 9.6 0.0 0.0 7.5 11.1
France 12.1 <0.1 19.4 30.1 0.9 31.5 11.7 19.2 16.4 7.8 15.7 15.7 20.9
Germany 11.8 <0.1 20.6 14.3 0.7 14.9 11.0 18.0 18.8 5.4 8.5 12.4 19.4
Greece 19.0 1.5 32.5 73.2 67.1 70.4 38.6 75.1 38.5 95.6 95.9 60.8 58.1
Hungary 16.9 0.0 27.2 37.6 1.0 36.2 20.7 36.8 25.6 61.2 67.8 29.1 32.8
Iceland 4.7 0.0 10.1 0.0 0.0 0.0 0.0 5.9 23.5 0.0 0.0 4.2 10.0
Ireland 12.4 <0.1 24.1 15.5 0.9 15.7 12.5 12.1 15.0 0.0 3.2 12.5 22.1
Italy 31.2 0.4 45.5 59.3 37.2 60.4 23.0 28.3 30.1 79.9 80.6 40.7 49.5
Latvia 25.7 0.0 29.6 45.9 5.9 48.2 26.7 37.5 43.8 75.7 86.7 39.9 43.5
Lithuania 15.1 0.0 20.0 57.3 0.6 55.8 10.8 21.6 16.4 85.1 87.4 31.0 33.5
Luxembourg 13.6 0.0 29.2 35.9 1.3 42.3 10.0 19.4 22.5 0.0 25.0 17.0 30.5
Malta 14.9 0.3 42.4 22.5 8.8 37.3 12.5 12.5 15.0 42.9 42.9 16.8 39.0
Netherlands 7.0 0.0 14.0 9.8 0.1 10.2 3.5 6.1 9.0 1.9 4.7 7.3 13.1
Norway 6.1 0.1 11.9 7.4 0.0 6.1 7.1 11.6 8.4 0.0 3.0 6.6 10.6
Poland 15.2 <0.1 37.2 65.4 3.9 68.1 19.5 31.5 33.3 69.6 83.1 33.7 48.5
Portugal 16.8 0.1 30.2 48.6 6.4 48.8 19.9 22.4 23.4 52.2 51.2 26.1 34.4
Romania 22.7 0.8 30.4 68.9 38.7 64.7 48.1 54.9 52.4 85.3 90.9 50.7 53.2
Slovakia 31.2 0.0 42.0 62.4 3.3 68.1 31.1 46.2 48.4 32.4 46.5 42.2 50.8
Slovenia 13.8 0.4 25.8 25.1 0.4 34.5 17.5 23.8 22.4 45.0 55.0 17.1 27.7
Spain 15.4 0.1 33.4 23.0 3.8 24.8 15.6 24.7 27.5 64.2 68.9 18.1 31.8
Sweden 8.8 0.2 14.6 6.0 0.4 7.0 7.4 13.6 7.0 2.4 4.7 8.5 12.8
United Kingdom 10.0 0.1 17.1 9.9 0.6 9.5 5.3 7.3 9.8 2.6 4.8 9.6 15.3
3GC: third-generation cephalosporins; car: carbapenems; EU/EEA: European Union/European Economic Area; FQ: fluoroquinolones; IR: non-
susceptible isolates.
a Composite percentage of E. coli non-susceptible to third-generation cephalosporins, K. pneumoniae non-susceptible to third-generation 
cephalosporins, P. aeruginosa non-susceptible to carbapenems and Acinetobacter spp. non-susceptible to carbapenems among all tested E. 
coli, K. pneumoniae, P. aeruginosa and Acinetobacter spp. isolates.
b Composite percentage of E. coli non-susceptible to fluoroquinolones, K. pneumoniae non-susceptible to fluoroquinolones, P. aeruginosanon-
susceptible to fluoroquinolones and Acinetobacter spp. non-susceptible to fluoroquinolones among all tested E. coli, K. pneumoniae, P. 
aeruginosa and Acinetobacter spp. isolates.
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Figure 1
Distribution of fully susceptible (S) and non-susceptible (I or R) isolates in four Gram-negative species isolated from blood 
or cerebrospinal fluid, 30 EU/EEA countries, 2016 (n = 173,540)
A. Third-generation cephalosporins for Klebsiella pneumoniae and Escherichia coli, and
      carbapenems for Pseudomonas aeruginosa and Acinetobacter spp.
B. Fluoroquinolones for the four species
Escherichia coli S to 3GC
Escherichia coli IR to 3GC
Klebsiella pneumoniae S to 3GC
Klebsiella pneumoniae IR to 3GC
Pseudomonas aeruginosa S to car
Pseudomonas aeruginosa IR to car
Acinetobacter spp. S to car
Acinetobacter spp. IR to car
Escherichia coli S to FQ
Escherichia coli IR to FQ
Klebsiella pneumoniae S to FQ
Klebsiella pneumoniae IR to FQ
Pseudomonas aeruginosa S to FQ
Pseudomonas aeruginosa IR to FQ
Acinetobacter spp. S to FQ
Acinetobacter spp. IR to FQ
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3GC: third-generation cephalosporins; car: carbapenems; EU/EEA: European Union/European Economic Area; FQ: fluoroquinolones; I: 
intermediately susceptible; R: resistant; S: susceptible.
The countries are ranked by increasing proportion of Escherichia coli isolates. Colour shading: susceptible isolates; hatched areas: non-
susceptible isolates.
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(Table 1). The species distribution varied considerably 
between countries. Although E. coli remained the most 
commonly reported species in all 30 countries, the 
percentage of  E. coli  ranged from 31.9% (Greece) to 
81.0% (Iceland), with a median of 69.0%. For K. pneu-
moniae, the percentage ranged from 10.5% (Iceland) to 
34.3% (Romania), with a median of 17.5%. For P. aerugi-
nosa, the percentage ranged from 4.1% (Latvia) to 20.2% 
(Cyprus) (median 7.5%) and for Acinetobacter spp. from 
0.5% (Finland) to 22.1% (Greece) (median 1.9%). The 
combined percentage of the two PSEACI species among 
the total number of isolates ranged from 5.5% (Norway) 
to 39.2% (Greece), with a median of 10.1%.
Antibiotic non-susceptibility
Third-generation cephalosporins
The percentage of isolates with acquired non-suscep-
tibility to third-generation cephalosporins ranged from 
4.7% (Iceland) to 41.0% (Bulgaria) in  E. coli  (median: 
14.4%), from 0.0% (Iceland) to 75.9% (Bulgaria) in  K. 
pneumoniae(median: 31.1%) and from 0.0% (Iceland) 
to 48.1% (Romania) in  P. aeruginosa  (median: 12.5%) 
(Table 2).
Carbapenems
The percentage of isolates with acquired non-suscep-
tibility to carbapenems ranged from 0.0% (Croatia, 
Denmark, Estonia, Hungary, Iceland, Latvia, Lithuania, 
Luxembourg, the Netherlands and Slovakia) to 
1.5% (Greece) in  E. coli(median: < 0.1%), from 0.0% 
(Iceland and Norway) to 67.1% (Greece) in K. pneumo-
niae  (median: 1.0%), from 4.6% (Denmark) to 75.1% 
(Greece) in  P. aeruginosa  (median: 21.0%) and from 
0.0% (Denmark, Finland, Iceland, Ireland, Luxembourg 
and Norway) to 95.6% (Greece) in  Acinetobacter  spp. 
(median: 35.0%) (Table 2).
Fluoroquinolones
The percentage of isolates with acquired non-suscepti-
bility to fluoroquinolones ranged from 10.1% (Iceland) 
to 47.0% (Cyprus) in  E. coli  (median: 26.5%), from 0% 
(Iceland) to 70.4% (Greece) for K. pneumoniae (median: 
35.9%), from 5.0% (Denmark) to 52.4% (Romania) in P. 
aeruginosa  (median: 22.1%), and from 0% (Finland 
and Iceland) to 95.9% (Greece) in  Acinetobacter  spp. 
(median: 41.4%) (Table 2).
Combining the percentages of susceptible (S) 
and non-susceptible (I + R) isolates in each of 
the four Gram-negative species
Figure 1 shows, within each of the four Gram-negative 
species reported by the 30 countries, the distribution of 
isolates fully susceptible (S) and non-susceptible (I + R) 
to broad-spectrum β-lactams (third-generation cepha-
losporins for K. pneumoniae and E. coli, carbapenems 
for  P. aeruginosa  and  Acinetobacter  spp.) (Figure 1A) 
and to fluoroquinolones for the four species (Figure 1B). 
The sum of these non-susceptible isolates, expressed 
as the composite percentage of isolates intermedi-
ately susceptible and resistant to broad-spectrum 
β-lactams, ranged from 4.2% for Iceland and 6.6% 
for Norway to 15.7% for France and 18.1% for Spain, 
up to 57.4% for Bulgaria and 60.8% for Greece (Table 
2). In  Figure 1B, the composite percentage of isolates 
intermediately susceptible and resistant to fluoroqui-
nolones ranged from 10.0% for Iceland and 10.6% for 
Norway to 20.9% for France and 31.8% for Spain, up to 
52.8% for Bulgaria and 58.1% for Greece. Among the 
total of isolates from bloodstream infection involving 
the four Gram-negative species, the proportion of  E. 
coli  isolates susceptible to third-generation cephalo-
sporins ranged from 77.5% in Iceland to only 24.3% in 
Bulgaria, whereas the proportion of Acinetobacter spp. 
isolates non-susceptible to carbapenems ranged from 
0% in Denmark, Finland, Iceland, Ireland, Luxembourg 
and Norway to 21.7% in Greece.
Correlation between country-specific 
percentages of acquired non-susceptibility in 
the four species and proportion of Pseudomonas 
aeruginosa and Acinetobacter spp.
There was a strong positive correlation between the 
ranks of the country-specific percentages of non-sus-
ceptibility to third-generation cephalosporins and the 
percentage of PSEACI:  E. coli  (rho = 0.88, p < 0.0001) 
(Figure 2A),  K. pneumoniae  (rho = 0.82, p < 0.0001) 
and  P. aeruginosa  (rho = 0.78, p < 0.0001). Similar 
positive correlations were found for non-susceptibility 
to carbapenems in  K. pneumoniae  (rho = 0.76, 
p < 0.0001),  P. aeruginosa  (rho = 0.85, p < 0.0001) 
and  Acinetobacter  spp. (rho 0.85, p < 0.0001). The 
correlation was more moderate and not statistically 
significant for non-susceptibility to carbapenems 
in  E. coli  (r = 0.33, p = 0.077) (Figure 2B). Finally, this 
correlation was also strong for non-susceptibility to 
fluoroquinolones in  E. coli  (rho = 0.75, p < 0.0001)  K. 
pneumoniae  (rho = 079, p < 0.0001), P. aeruginosa 
(rho = 0.79, p < 0.0001) and  Acinetobacter  spp. 
(rho = 0.85, p < 0.0001) (Figure 2C).
Discussion
The intrinsic resistance profiles of different bac-
teria are reflected in the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) expert 
rules [5] as well as in the number of antimicrobial drugs 
that must be considered to define acquired MDR/XDR/
PDR patterns [6]. As a consequence, for Gram-negative 
bacteria, identification of the species isolated from a 
positive blood culture provides immediate informa-
tion to the microbiologist and the clinician about which 
antimicrobials should not be used because of intrin-
sic resistance in that species. This is one of the major 
reasons for the development of rapid methods for bac-
terial species identification, such as matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) 
mass-spectrometry. In addition, acquired resistance 
is recognised as a major global public health issue 
[11,12] because it jeopardises the effectiveness of anti-
microbial drugs that are normally active against intrin-
sically multi-susceptible species such as  E. coli  and 
because it further reduces the possibility to treat 
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infections with species that are already intrinsically 
resistant to many antimicrobial drugs such as  P. 
aeruginosa and Acinetobacter spp.
The results presented here, based on an analysis 
of EARS-Net data for the year 2016 and focusing on 
four major Gram-negative species (E. coli,  K. pneumo-
niae,  P. aeruginosa  and  Acinetobacter  spp.) isolated 
from bloodstream infections, clearly show significant 
statistical association between the distribution 
of species, and the percentages of acquired non-
susceptibility to major antibiotic groups. All but 
one correlation were statistically significant, with 
Spearman’s rank correlation coefficient being > 0.75 
for 10 of the 11 pairs of variables tested, which 
is generally considered as indicating a strong 
correlation [13,14]. In short, the higher the propor-
tion of the two most intrinsically resistant species  P. 
aeruginosa  and  Acinetobacter  spp., the higher the 
percentages of acquired non-susceptibility in E. coli, K. 
pneumoniae,  P. aeruginosa  and  Acinetobacter  spp., 
a point that directly indicates the burden of intrinsic 
resistance. Consequently, there were, at one extremity 
of the EU/EEA gradient, countries with a very low 
Figure 2
Scattergrams showing the sum of proportions of Pseudomonas aeruginosa and Acinetobacter spp. combined (PSEACI) (n = 
20,995) among four Gram-negative speciesa and proportions of various acquired non-susceptibility and species, 30 EU/EEA 
countries, 2016
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proportion of bloodstream infections caused by the 
two most intrinsically resistant species together with 
low percentages of isolates with acquired non-suscep-
tibility in any of the four Gram-negative species. At the 
opposite extremity of the EU/EEA gradient, countries 
with high percentages of bloodstream isolates caused 
by the two most intrinsically resistant species had high 
percentages of isolates with acquired non-suscepti-
bility in all the four species. The weak statistical link 
noted for carbapenem non-susceptibility in E. coli could 
be due to very low percentages of non-susceptibility 
reported from a majority of the countries [1].
Statistical association is not equal to causation and 
the correlations presented in this study do not mean 
that there is a cause-and-effect relationship between 
intrinsic and acquired resistance. However, we can 
hypothesise that the two major driving forces of anti-
biotic resistance, i.e. the use of antibiotics acting as 
a selective pressure on resistant bacteria and the 
spread of the selected antibiotic-resistant bacteria by 
cross-transmission between humans, animals and the 
environment, apply to both the intrinsically resistant 
species such as  P. aeruginosa  and  Acinetobacter  spp. 
(and to a lesser extent  K. pneumoniae), and to 
strains with acquired resistance (in the present 
study: resistance to β-lactams or fluoroquinolones). 
Antibiotic use has a strong selective effect on  P. aer-
uginosa  and  Acinetobacter  spp [15,16] and on strains 
with acquired resistance traits in many species [17-
20]. Host-to-host cross-transmission of  P. aerugi-
nosa and Acinetobacter spp [21,22] and of strains with 
acquired resistance traits e.g. in enterobacteria [23,24] 
also plays a crucial role in the spread of resistance. 
Indeed, the available comparative data suggest that 
the EU/EEA countries that in our study had the high-
est proportion of intrinsically resistant species and 
percentages of isolates with acquired resistance, gen-
erally also have the highest antibiotic consumption in 
humans (in particular broad-spectrum β-lactams and 
fluoroquinolones) and the lowest levels of preven-
tive measures against cross-transmission of microor-
ganisms in hospitals such as consumption of alcohol 
hand rub solutions, proportion of rooms with a single 
bed and staffing of infection control teams [2,25,26]. 
Differences in healthcare systems or, possibly, climate 
issues could also be involved in the discrepancies 
between countries.
This study has several limitations. Firstly, although 
a very large number of isolates from bloodstream 
infections (n = 173,540) were analysed, this study 
only included the four Gram-negative species cov-
ered by EARS-Net (E. coli, K. pneumoniae, P. aerugi-
nosa  and  Acinetobacter  spp.) and did not cover other 
species such as Enterobacter cloacae, Serratia marces-
cens  or  Proteus mirabilis.  However, the included four 
species taken together constitute the majority of inva-
sive aerobic Gram-negative isolates in many studies: 
78% of bloodstream infections recorded by the SENTRY 
surveillance programme organised in Europe from 1997 
to 1998 [27], 73% in the European point prevalence sur-
vey coordinated by ECDC in 2011 and 2012 [2] and 74% 
in a meta-analysis on infections recorded in develop-
ing countries [28]. Secondly, our study did not cover 
all antibiotics but only a selection of broad-spectrum 
β-lactams (third-generation cephalosporins and car-
bapenems) and the fluoroquinolones, widely used for 
treating bacteraemia caused Gram-negative species. 
However, we observed in the same data source simi-
lar types of correlations with aminoglycosides, another 
major class of antibiotics used for treating such severe 
infections (data not shown). Finally, the patient case-
mix, which depends on the types of included hospitals 
and on the frequency of blood culture sampling in each 
country, might have had an impact on the reported 
resistance percentages. Importantly, in the EARS-Net 
reports that provide detailed information on the num-
ber of laboratories and characteristics of the hospitals 
included, there were no marked differences between 
countries with low and high resistance percentages 
concerning the proportions of tertiary care hospital 
beds and intensive care unit beds, two types of hospi-
tal settings where resistance rates are usually the high-
est [1,29]. In addition, the representativeness of the 
population sample for 2016 data has been assessed 
as high in 23 of the 30 countries [29]. However, there 
was a trend towards a lower number of blood cul-
ture sets taken per 1,000 patient days in some of the 
countries with the highest percentages of resistance 
[29], which may have led us to overestimate the per-
centage of acquired resistance or the percentage of 
PSEACI in these countries. Concerning the quality of 
antibiotic susceptibility testing in EARS-Net, the wide-
spread implementation of EUCAST clinical breakpoints 
in Europe and the high proportion of laboratories that 
participated in 2016 in the annual EARS-Net external 
quality assessment exercises with satisfactory results 
[1] greatly helps to ascertain the ability of the EU/EEA 
countries to report robust and trustworthy antimicro-
bial resistance data to EARS-Net.
Conclusion
We observed a strong correlation in bloodstream infec-
tions between on the one hand the countries with most 
intrinsically resistant Gram-negative species, indicat-
ing the burden of intrinsic resistance, and on the other 
hand the percentage of acquired non-susceptibility 
in these species. This important information adds to 
the already well-established arguments for a strong 
reduction in the consumption of antibiotics, particu-
larly those with broad-spectrum activity, which exert a 
selective pressure on all types of resistant bacteria. It 
also reinforces the crucial importance of measures to 
prevent host-to-host cross-transmission of antibiotic-
resistant microorganisms, not only to control acquired 
resistance in every bacterial species but also to limit 
the burden of infections caused by species such as P. 
aeruginosa  and  Acinetobacter  spp.,  in which intrinsic 
resistance per se represents a therapeutic problem.
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